News

Latest News:

MC2 Therapeutics A/S announces first patient dosed in EU Phase 3 trial in psoriasis vulgaris

POSTED: January 6, 2019

  • First patient dosed in Phase 3 trial assessing the safety and efficacy of MC2-01  Cream in EU
  •  Topline results are expected in Q3 2019

Copenhagen, January 6th, 2019 – MC2 Therapeutics A/S, ...

READ FULL ARTICLE >

Upcoming Events:

January 6th, 2019

The 6th Annual Dermatology Summit

READ MORE >

January 7th - 10th, 2019

J.P. Morgan 37th Annual Healthcare Conference 2019 (San Francisco)

READ MORE >

October 25th, 2018

OIS@AAO – Ophthalmology Innovation Summit

READ MORE >

September 12th – 16th, 2018

European Academy of Dermatology & Venereology (EADV)

READ MORE >

May 14th – 16th, 2018

Bio€quity Europe

READ MORE >

January 8th – 11th, 2018

J.P. Morgan 36th Annual Healthcare Conference 2018 (San Francisco)

READ MORE >

November 15th – 16th, 2017

Jefferies 2017 London Healthcare Conference

READ MORE >

November 9th, 2017

OIS@AAO – Ophthalmology Innovation Summit

READ MORE >

© mc2 therapeautics 2016